Michele is the Chief Development Officer of Ventus Therapeutics. Michele holds a Ph.D. in immunology and has 20 years of experience in pharmaceutical development with 8 drug approvals and over a dozen initial INDs.
Prior to Ventus, Michele was VP of Regulatory, Quality, and Project Management at Medivation, where she led the NDA of enzalutamide in prostate cancer. She then joined Labrys Biologicals as the VP of Regulatory and Quality and was critical to the development of Fremanezumab (Ajovy). After Labrys, Michele worked at Portola Pharmaceuticals as VP of Program Management and Clinical Development Operations. In this capacity, she built the Development Operations organization (program management, medical writing, clinical operations, and biometrics), leading to the US approval of the Factor Xa inhibitor, betrixaban, and the Factor Xa reversals agent, andexanet alfa, for which she was Project Team Lead. She also supported the development of cerdulatinib, a dual syk-jak kinase inhibitor. More recently, she was the Chief Development Officer at Nuvation Bio.
Michele earned her Ph.D. in Molecular Immunology from UT Southwestern Medical Center.